Albert Bourla, Pfizer CEO (Evan Vucci/AP Images)

Pfiz­er doles out $2.3B for blood can­cer play­er to flesh out its end-of-decade on­col­o­gy port­fo­lio

As its Covid-19 vac­cine rakes in cash, Pfiz­er is in a po­si­tion to move bold­ly as it looks at the hazy end of the cur­rent decade. Seek­ing peace of mind, the drug­mak­er has signed a rich deal with a fa­mil­iar CD47 play­er to help firm up its next-gen game plans.

Pfiz­er will pay $2.26 bil­lion to ac­quire Cana­di­an biotech Tril­li­um Ther­a­peu­tics and its lead mol­e­cules tar­get­ing the sig­nal reg­u­la­to­ry pro­tein-α (SIR­Pα)–CD47 ax­is for blood can­cers as part of a push to add fire­pow­er to the Big Phar­ma’s on­col­o­gy port­fo­lio for the late 2020s, the part­ners said in a re­lease Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.